Key facts
- This page summarizes Arjun Jj Desai's Form 4 filing for TriSalus Life Sciences, Inc. (TLSI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Jul 2024, 20:33.
Arjun Jj Desai - 01 Jul 2024 Form 4 Insider Report for TriSalus Life Sciences, Inc. (TLSI)
- Reporting relationship
- Director
- Issuer ticker
- TLSI
- Reported as of
- 01 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2024, 20:33:55 UTC
- Prior SEC filing
- 10 Jun 2024
- Next SEC filing
- 21 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sean Murphy, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Arjun Jj Desai filed Form 4 for TriSalus Life Sciences, Inc. (TLSI) on 02 Jul 2024.
Change
- Previous filing in this sequence was filed on 10 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TLSI
transaction
Common Stock
Award
- Transaction value
- Shares
- +74,000
- Change %
- +36%
- Price
- Shares after
- 277,127
- Date
- 01 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLSI
transaction
Derivative
Redeemable Warrants
Disposed to Issuer
- Transaction value
- Shares
- -246,667
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 01 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 246,667
- Exercise price
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
As previously disclosed, on May 24, 2024, TriSalus Life Sciences, Inc. (the "Issuer"), announced the commencement of its offer (the "Issuer Tender Offer") to all holders of each class of certain outstanding warrants (the "Warrants"), consisting of (a) the Issuer's publicly-traded Warrants currently listed on the Nasdaq Global Market under the symbol "TLSIW", (b) certain Warrants issued in a private placement transaction occurring simultaneously with the closing of the initial public offering of the Issuer and (c) certain Warrants issued for working capital requirements and payment of certain expenses of the Issuer, each identified in the Prospectus/Offer to Exchange that forms a part of the Issuer's Registration Statement on Form S-4 (Registration No. 333- 279691), filed with the Securities and Exchange Commission on May 24, 2024, to receive 0.3 shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), [continued on footnote 2]
Footnote F2
[continued from footnote 1] in exchange for each Warrant tendered by the holder and exchanged pursuant to the Issuer Tender Offer. Pursuant to the Issuer Tender Offer, the Reporting Person tendered 246,667 Warrants in exchange for 74,000 shares of Common Stock.
Footnote F3
Represents Warrants received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement.
Footnote F4
The Warrants expire on August 9, 2028, or earlier upon redemption or liquidation.